Compare URGN & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | URGN | RBCAA |
|---|---|---|
| Founded | 2004 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2016 | 1998 |
| Metric | URGN | RBCAA |
|---|---|---|
| Price | $40.70 | $91.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 579.2K | 83.0K |
| Earning Date | 11-05-2026 | 10-16-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | $1,128,000.00 | ★ $417,495,000.00 |
| Revenue This Year | $193.48 | N/A |
| Revenue Next Year | $68.06 | $3.20 |
| P/E Ratio | ★ N/A | $119.77 |
| Revenue Growth | N/A | ★ 8.50 |
| 52 Week Low | $15.86 | $63.97 |
| 52 Week High | $50.81 | $102.22 |
| Indicator | URGN | RBCAA |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 32.16 |
| Support Level | $40.94 | $88.24 |
| Resistance Level | $44.63 | $93.54 |
| Average True Range (ATR) | 1.63 | 1.60 |
| MACD | -0.23 | -0.42 |
| Stochastic Oscillator | 23.37 | 5.68 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.